Nose to Brain Drug Delivery of Aerosolized Nanoparticles

Aida Maaz¹, Ian Blagbrough¹, Robert Price¹, Paul De Bank¹

¹Department of Pharmacy and Pharmacology, University of Bath, Bath, BA2 7AY, U.K.

Background: Our research aim is to assess the performance of intranasal nanoformulations in vitro, particularly for CNS targeting delivery via the uppermost region within the nasal cavity. For the first time and in order to achieve, deep penetration into nasal cavity, this project is focused on the delivery of nanoparticles via a liquified propellant contained within a pressurized metallic canister. The design of the nanocarriers in terms of their shape, size, surface charge and functionalization will be optimized to enhance the efficiency of carrier/drug in vitro deposition in the olfactory region. In addition, aerosol/device related parameters as well as administration instructions (cast tilting and actuator tip orientation) will also be investigated for nasal regional localization.

Methods: Firstly, spherical Au seeds were synthesized: 100 mL of HAuCl₄.3H₂O aqueous solution was boiled for 2h and then the reducing agent sodium citrate dihydrate was added with continuous stirring to produce a rose wine type solution, referring to the citrate capped seed’s formation. AuNFs were prepared in a 10 mL vial of ultra-pure water by adding specific amounts of the pre-prepared seeds followed by HAuCl₄.3H₂O, silver nitrate as a shape directing agent, methoxy-PEG thiol as stabilizing agent and dopamine as both a reducing agent and model therapeutic, followed by stirring for two hours. The resulting dark blue color solution reflected the successful growth of gold nanoparticles, which were concentrated by evaporation (F1) or freeze drying (F2) to be further suspended within metallic canister with a hydrofluoroalkane propellant and delivered via a bespoke nasal device. Upon actuation, the spray jet nozzle creates high velocity droplets for transportation of the therapeutic particles in to the nasal cavity. Glass collection apparatus (Copley Scientific, UK) was used to test the integrity of the AuNFs formulations after filling within the cans. F1 and F2- filled canisters were tested with adjusted flow rate at 15 ± 0.2 L/min. The samples were firstly primed by shaking the canisters 20 times and sonicating for 90 seconds, 10 actuations were carried out for each sample and finally the spray mist was collected on a mixed cellulose ester membrane located at the top of the tube to receive the fired shot. A piece of mica and carbon grid was stuck on the membrane for SEM and TEM analysis, respectively. In vitro deposition studies will be performed using nasal cast model recreated from MRI scans of human nasal airways. The model 3D printed in house to build copies with separated distinct regions.

Results: Both gold nanosuspension F1 and F2 were characterized and compared before and after the filling and spraying by the metered dose device. The concentrated gold nanosuspension was dark blue in color. DLS measurements showed that both formulations had a size range of 132.6 ± 0.95 nm and 137.8 ± 0.7 nm, were highly monodisperse, with PDI of 0.003 to 0.017, and positively charged (Z.P 5.42 ± 0.24 mV). These results were further confirmed with TEM imaging. Interestingly, no changes were observed in terms of the shape and the size of the prepared particles following the filling within the propellent system. However, very few particles could be detected on the TEM grids, so SEM-EDX analysis of the upper membrane was carried out to investigate elemental gold within the receiver membrane. Tiny fluorescent dots distributed throughout the membrane were observed and they belong to Au element.

Conclusions: Aerosolized AuNFs were successfully prepared as a pioneer nasal system for further brain targeting. Their simple preparation, flexible morphologies together with high stability within the propellent based devices make them excellent candidates for nose to brain drug delivery studies.